Inovio Pharmaceuticals, Inc. (INO)
1.16
-0.05
(-4.13%)
USD |
NASDAQ |
Oct 02, 16:00
1.18
+0.02
(+1.72%)
After-Hours: 20:00
Inovio Pharmaceuticals Net Income (Quarterly) : -6.012M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.012M |
| March 31, 2026 | -19.68M |
| December 31, 2025 | 3.765M |
| September 30, 2025 | -45.50M |
| June 30, 2025 | -23.52M |
| March 31, 2025 | -19.69M |
| December 31, 2024 | -19.38M |
| September 30, 2024 | -25.17M |
| June 30, 2024 | -32.24M |
| March 31, 2024 | -30.47M |
| December 31, 2023 | -25.00M |
| September 30, 2023 | -33.93M |
| June 30, 2023 | -35.53M |
| March 31, 2023 | -40.65M |
| December 31, 2022 | -54.46M |
| September 30, 2022 | -37.78M |
| June 30, 2022 | -108.50M |
| March 31, 2022 | -79.07M |
| December 31, 2021 | -106.95M |
| September 30, 2021 | -60.17M |
| June 30, 2021 | -82.14M |
| March 31, 2021 | -54.40M |
| December 31, 2020 | -24.34M |
| September 30, 2020 | 19.17M |
| June 30, 2020 | -129.17M |
| Date | Value |
|---|---|
| March 31, 2020 | -33.14M |
| December 31, 2019 | -38.15M |
| September 30, 2019 | -23.54M |
| June 30, 2019 | -29.58M |
| March 31, 2019 | -29.29M |
| December 31, 2018 | -32.96M |
| September 30, 2018 | -25.02M |
| June 30, 2018 | -6.639M |
| March 31, 2018 | -32.35M |
| December 31, 2017 | -21.51M |
| September 30, 2017 | -34.13M |
| June 30, 2017 | -9.479M |
| March 31, 2017 | -23.09M |
| December 31, 2016 | -26.23M |
| September 30, 2016 | -20.76M |
| June 30, 2016 | -18.70M |
| March 31, 2016 | -8.043M |
| December 31, 2015 | -17.95M |
| September 30, 2015 | 5.594M |
| June 30, 2015 | -6.162M |
| March 31, 2015 | -10.58M |
| December 31, 2014 | -7.412M |
| September 30, 2014 | -7.179M |
| June 30, 2014 | -10.72M |
| March 31, 2014 | -10.83M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Nektar Therapeutics | -40.62M |
| Ironwood Pharmaceuticals, Inc. | 51.29M |
| Fortress Biotech, Inc. | 0.602M |
| Tonix Pharmaceuticals Holding Corp. | -40.55M |
| Kura Oncology, Inc. | -68.33M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.012M |
| EPS Diluted (Quarterly) | -0.0737 |
| Enterprise Value | 66.84M |
| Earnings Yield | -101.4% |
| Normalized Earnings Yield | -108.11 |